Who should receive a statin these days? Lessons from recent clinical trials

Journal of Internal Medicine

Volumn 260, Issue 4, 2006, Pages 305-319

  Shepherd, J ^a,b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b NHS Greater Glasgow and Clyde Clinical Biochemistry Service   (United Kingdom)

Author keywords

Cardiovascular disease prevention; Cholesterol; Low density lipoprotein receptor; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CARDIOVASCULAR AGENT; CLOFIBRATE; COLESTYRAMINE; COMPACTIN; CREATINE KINASE; FIBRINOLYTIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE COURSE; DRUG MECHANISM; DRUG WITHDRAWAL; HEART INFARCTION; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; MEDICAL EDUCATION; METABOLIC SYNDROME X; MYOPATHY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RHABDOMYOLYSIS; STROKE; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; AGED; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CHOLESTEROL; CLINICAL PROTOCOLS; CLINICAL TRIALS; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCULAR DISEASES; MYOCARDIAL INFARCTION; RECURRENCE;

EID: 33748534819     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01700.x     Document Type: Review

References (50)

1. Endo A. The discovery and development of the statins. In: Gaw A, Packard CJ, Shepherd J, eds. Statins: The HMG CoA Reductase Inhibitors in Perspective, 2nd edn. London: Taylor and Francis, 2004; 32-44.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB. The prediction of coronary heart disease and atherosclerosis. In: Rifkind BM, Levy RI, eds. Hyperlipidemia: Diagnosis and Therapy. New York: Grune and Stratton Inc., 1977; 71-8.
3. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Nobel Lecture 9 December 1985. http://nobelprize.org/nobelprizes/ medicine/laureates/1985/brown-goldstein-lecture.pdf.
4. Roberts WC. The underused miracle: the statin drugs are to atherosclerosis what penicillin was to infectious disease. Am J Cardiol 1996; 78: 377-8.
5. Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 1980; 35: 259-66.
6. Mabuchi H, Sakai T, Sakai Y et al. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. N Engl J Med 1983; 308: 609-13.
7. Committee of Principal Investigators. WHO Clofibrate Trial. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-118.
8. Committee of Principal Investigators. WHO Clofibrate Trial. A co-operating trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow up report. Lancet 1980; ii: 379-85.
9. The Lipid Research Clinics Program. The Coronary Primary Prevention Trial: design and implementation. Chron Dis 1979; 32: 609-31.
10. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
11. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74.
12. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged men with dyslipidemia: safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
13. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
14. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615-22.
15. Chambless L, Keil U, Dobson A et al. Population versus clinical view of case fatality from acute coronary heart disease. Results from the WHO MONICA Project, 1985-1990. Circulation 1997; 96: 3849-59.
16. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. Atherosclerosis 2004; 173: 381-91.
17. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J 2004; 68: 860-7.
18. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
19. Sacks FM, Moye LA, Davis BA et al. Relationship between plasma LDL cholesterol concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol And Recurrent Events Trial (CARE). Circulation 1998; 97: 1446-52.
20. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
21. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
22. Sever PS, Dahlhof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2004; 361: 1149-58.
23. Athyros V, Papageorgiou AA, Mercouris BR et al. Treatment with atorvastatin to the NCEP goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-8.
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised, placebo-controlled trial. Lancet 2002; 360: 7-22.
25. The PPP Project Investigators. Design, rationale and baseline characteristics of the prospective pravastatin pooling (PPP) project: a combined analysis of three large-scale randomised trials. Am J Cardiol 1995; 76: 899-905.
26. Byington RP, Davis BR, Plehn JF et al. for the PPP investigators. Reduction of stroke events with pravastatin. Circulation 2001; 103: 387-92.
27. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
28. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised, placebo-controlled trial. Lancet 2004; 364: 685-96.
29. Amarenco P, Tonkin AM. Statins for stroke prevention. Circulation 2004; 109(Suppl. III): 44-9.
30. SPARCL Investigators. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovasc Dis 2003; 16: 389-95.
31. Schwartz GG, Olsson AG, Ezekowitz MD et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 2001; 285: 1711-8.
32. de Lemos JA, Blazing JA, Wiviott SD et al. Early intensive versus a delayed conservative statin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-16.
33. Boersma E, Mercado N, Poldermans D et al. Acute myocardial infarction. Lancet 2003; 361: 847-58.
34. Norris RM, Caughey DE, Mercer CJ et al. prognosis after myocardial infarction. Br Heart J 1974; 36: 786-90.
35. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators (ASSENT-2). Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction. Lancet 1999; 354: 716-22.
36. The ASSENT-3 Trial Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximas or unfractionated heparin. Lancet 2001; 358: 605-13.
37. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy. The GUSTO V randomised trial. Lancet 2001; 357: 1905-14.
38. Waters D, Schwartz GG, Olsson AG. The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins? Curr Control Trials Cardiovasc Med 2001; 2: 111-4.
39. Acevedo M, Sprecher D. Statins in acute coronary syndromes: start them in the hospital. Cleve Clin J Med 2002; 69: 25-37.
40. Stenestrand U, Wallentin L. for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-6.
41. Aronow HD, Topol EJ, Roe MT et al. Effect of lipid lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357: 1063-8.
42. Cannon CP, McCabe CH, Bentley J, Braunwald E. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPOS-TIMI 16. JACC 2001; 87(Suppl. A): 334A (Abstract).
43. Cannon CP, Braunwald E, McCabe CH et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
44. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the National Cholesterol Education Program Expert Panel. JAMA 2001; 285: 2486-97.
45. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
46. Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. Diabetes Care 2006; 29: 1220-6.
47. Pedersen JR, Faergeman O, Kastelein JJ et al. High dose atorvastatin versus usual dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomised controlled trial. JAMA 2005; 294: 1437-45.
48. Shepherd J, Wenger NK, Kastelein JP for the Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) Study. JACC 2006 (in press).
49. Grundy SM. The issue of statin safety. Circulation 2005; 111: 3016-9.
50. McKenney JM (ed.). Report of the National Lipid Association's Statin Safety Task Force. Am J Cardiol 2006; 97(Suppl. 1): S1-S98.